Drug recall · October 4, 2023
Eligard recall
Why: Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.
- Lots / codes
Lot: 13635A1, Exp. 07/31/2024
- Quantity
- 2990 cartons
- Company
- Tolmar, Inc., Fort Collins, CO
- Distribution
- Nationwide in the US.
- Initiated
- September 12, 2023 · Voluntary: Firm initiated
- Classified
- September 27, 2023
- Reported
- October 4, 2023
- Ended
- October 3, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Leuprolide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.